Drug Trial Radar · NCT06979518
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
Last checked: Nov 19, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
May 20, 2025
Primary completion
Apr 22, 2026
Study completion Apr 22, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to assess the ethnic sensitivity of GSK3862995B in terms of safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) in healthy participants of Chinese, Japanese, and European ancestry to enable the inclusion of Chinese and Japanese participants in future global studies.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
GSK3862995BDrug
GSK3862995B will be administered.
PlaceboDrug
Matching placebo will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AE)Time frame: Up to Week 44 (End of follow up visit)
- Number of Participants with Serious Adverse Events (SAE)Time frame: Up to Week 44 (End of follow up visit)
- Number of Participants with Clinically Significant Changes in Clinical Laboratory ValuesTime frame: Up to Week 36
- Number of Participants with Clinically Significant Changes in Vital SignsTime frame: Up to Week 36
- Number of Participants with Clinically Significant Changes in 12-lead (Electrocardiogram (ECG)Time frame: Up to Week 36
- Area Under the Serum Concentration-time Curve Extrapolated to Infinity (AUC[0-inf]) of GSK3862995BTime frame: Up to Week 36
- Maximum Observed Concentration (Cmax) of GSK3862995BTime frame: Up to Week 36
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Cypress, California
GSK Investigational Site
Las Vegas, Nevada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.